In den USA hat das Unternehmen Eirion Therapeutics eine Pressemitteilung zu ihrem Wirkstoff ET-02 herausgegeben.
"Controlled non-clinical studies of human scalp tissue affected by androgenic alopecia, ET-02 demonstrated approximately twice the hair growth compared to a control treatment over approximately 4 months, which was statistically significant, and amounted to approximately three times the hair growth per centimeter over that which was observed in minoxidil clinical trials that were 12 months in duration."